Sema4: A Patient-Centered Health Intelligence Company

Advancing Healthcare

through data-driven insights

A Health Intelligence Company That Puts Patients in the Center

Sema4 is founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease.

Learn more

Centrellis™

Our unique analytics platform, Centrellis, allows us to offer advanced tools to help providers better manage data for patient populations, launch new clinical studies, and easily compare patient outcomes across a healthcare system.

Learn more

Women’s Health

From pregnancy planning to expanded carrier screening, we deploy robust science and cutting-edge tools to give patients more actionable information all along the family journey through advanced genomic testing.

Learn more

Precision Oncology

Our family of precision oncology products and services, Sema4 Signal™, provides data-driven care solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests.

Learn more

Biopharma

Sema4 offers an extensive portfolio of health information solutions, including pre-clinical and clinical trial support, analytics for actionable insights, and advanced sequencing services, to drive informed decision-making across the drug discovery, development, and commercialization lifecycle.

Learn more

Robust Research

Sema4’s internationally recognized research is run by world leaders in data science, network modeling, multiscale biotechnology, and genomics. We’ve published more than 1,000 peer-reviewed publications in the last five years and remain committed to making new biological discoveries.

Learn more

Latest News

August 2nd, 2021

Sema4 to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021

Sema4 will release financial results for the second quarter of 2021 after the market close on August 16th.

July 22nd, 2021

Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company

Sema4 has announced the completion of its business combination with CM Life Sciences and will debut on Nasdaq under the ticker symbol “SMFR.”

July 7th, 2021

Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors

Jason Ryan has been appointed to Sema4’s Board of Directors. Jason brings an impressive background in finance and scaling businesses.

Featured In

Awards and Recognition